Education
About Us
Working with TipRanks
Follow Us
Vuong Trieu Insider Profile
4 Followers
Vuong Trieu, CSO, Director at Sorrento Therapeutics, holds 116.95M shares in Oncotelic Therapeutics (Ticker: OTLC), holds 3.01M shares in Sorrento Therapeutics (Ticker: SRNE).
Vuong Trieu Sorrento Therapeutics (SRNE)CSO, Director
Sorrento Therapeutics (SRNE)
CSO, Director
Ranked #52,560 out of 102,596 Corporate Insiders
Profitable Transactions
7 out of 13 Profitable Transactions
Average Return
-0.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Vuong Trieu holds in companies
Most Profitable Insider Trade
The most profitable trade made by Vuong Trieu
Vuong Trieu's Trading History
Sorrento Therapeutics
Sep 19, 2013
CSO, Director
Uninformative Buy
―
$30.07K
Oncotelic Therapeutics
Jul 10, 2025
Chairman & CEO, Director, Ten Percent Owner
Uninformative Buy
―
$5.85M
List of latest transactions for each holding click on a transaction to see Vuong Trieu's performance on stock
You May Also Like
Vuong Trieu insider profile FAQ
What is the percentage of profitable transactions made by Vuong Trieu?
The percentage of profitable transactions made by Vuong Trieu is 54%.
What is the average return per transaction made by Vuong Trieu?
The average return per transaction made by Vuong Trieu is -0.30%.
What stocks does Vuong Trieu hold?
Vuong Trieu holds: SRNE, OTLC stocks.
What was Vuong Trieu’s latest transaction?
Vuong Trieu latest transaction was an Uninformative Buy of ―.
What was Vuong Trieu's most profitable transaction?
Vuong Trieu’s most profitable transaction was an Informative Buy of OTLC stock on January 31, 2025. The return on the trade was 66.60%.
What is Vuong Trieu's role in Sorrento Therapeutics?
Vuong Trieu's role in Sorrento Therapeutics is CSO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.